Cutaneous Melanoma: AJCC 8 Staging, BRAF Targeting, and Checkpoint Inhibitors

Cutaneous Melanoma: AJCC 8 Staging, BRAF Targeting, and Checkpoint Inhibitors

OncologyAJCC 8th EditionBRAF/MEK + ICIStage III-IV Adjuvant

Executive Summary

Cutaneous melanoma is the most lethal common skin cancer, with rising incidence (US lifetime risk approximately 1 in 30) but improving outcomes from molecular and immune therapy advances. Diagnosis follows the ABCDE clinical assessment with biopsy-proven histology and Breslow thickness measurement. Sentinel lymph node biopsy is recommended for primary melanomas with Breslow thickness greater than 0.8 mm or thinner with adverse features. AJCC 8th edition staging combines Breslow thickness, ulceration, mitotic rate (no longer in T1 sub-classification but retained as a prognostic biomarker), nodal involvement, and distant metastasis with serum LDH stratification of M1 disease. Treatment of stage III-IV disease has been transformed: anti-PD1 monotherapy (pembrolizumab 200 mg IV q3wk or nivolumab 480 mg IV q4wk), combination ipilimumab plus nivolumab, and BRAF/MEK targeted combinations (dabrafenib + trametinib, encorafenib + binimetinib) have raised 5-year overall survival in metastatic melanoma from less than 10% (pre-2011 era) to greater than 50% in selected populations. Adjuvant immunotherapy (nivolumab or pembrolizumab × 12 months) reduces recurrence in resected stage III-IV disease. Immune-related adverse event recognition and management is now a core competency for any clinician treating melanoma.

100kUS new cases per year
40-50%Tumors BRAF-mutant
>50%5-yr OS metastatic w/ ICI
93%5-yr survival stage I

S1. Epidemiology, Risk Factors, and Subtypes

Cutaneous melanoma originates from neural-crest-derived melanocytes located in the basal epidermis, hair follicles, and (less commonly) mucosal surfaces, uveal tract, and meninges. Annual US incidence has tripled over four decades and now exceeds 100,000 new cases, with a lifetime risk of approximately 1 in 30 for non-Hispanic White individuals. Mortality has plateaued and begun declining since 2014 due to immunotherapy, despite continued incidence rise. Major risk factors are intermittent intense sun exposure (especially blistering childhood sunburns), high nevus count (greater than 50), atypical/dysplastic nevi, fair skin (Fitzpatrick I-II), red hair (MC1R variants), family history, immunosuppression (transplant recipients have 2-3 fold risk), and hereditary syndromes (CDKN2A, CDK4, BAP1, POT1 mutations).

Histologic subtypes

SubtypeFrequencyDistinctive featuresMolecular signature
Superficial spreading70%Trunk (men), legs (women); horizontal radial growth phase years before vertical growth; intermittent sun exposure patternBRAF V600E common (40-50%)
Nodular15-20%Vertical growth from outset, often thicker at presentation, faster growing, worse prognosis stage-for-stageBRAF or NRAS mutations
Lentigo maligna melanoma5-10%Sun-damaged skin (face/neck) of older patients; in situ phase (lentigo maligna) present years; large irregular maculeNF1 inactivation, low BRAF
Acral lentiginous2-5% (overall); 35-60% in Asian/BlackPalms, soles, subungual; not UV-related; later diagnosis; worse prognosisKIT mutations more common; BRAF less
Desmoplastic<5%Spindle cell variant on chronically sun-damaged skin; high local recurrence; perineural invasionHigh mutation burden; favorable ICI response

Mucosal melanoma (oral, vulvovaginal, anorectal, sinonasal) and uveal melanoma are biologically distinct from cutaneous melanoma — different mutation profiles (uveal: GNAQ/GNA11; mucosal: KIT, low TMB), different responses to immunotherapy (lower in mucosal and uveal), and separate AJCC staging systems.

Cutaneous Melanoma — Lesion Morphology Skin lesion morphology classification showing 8 lesion types Cutaneous Melanoma — Lesion Morphology Macule Flat, <1cm color change Patch Flat, >1cm color change Papule Raised solid, <1cm Plaque Raised flat-topped, >1cm Nodule Solid, 1-2cm deep Vesicle Fluid-filled, <1cm Bulla Fluid-filled, >1cm Pustule Pus-filled
Cutaneous Melanoma — Lesion Morphology

S2. Diagnosis: ABCDE, Dermoscopy, and Biopsy

Clinical assessment begins with the ABCDE criteria for pigmented lesions: Asymmetry, Border irregularity, Color variegation, Diameter greater than 6 mm, and Evolution (change in size, shape, color, surface, or symptoms). Patient-reported “ugly duckling” lesions (one nevus that looks different from the rest) deserves particular attention. The seven-point checklist (Glasgow) and the EFG criteria (Elevated, Firm, Growing) for nodular melanoma supplement ABCDE.

Dermoscopy

Polarized dermoscopy increases diagnostic accuracy by 30% over naked-eye exam in trained hands. Suggestive features for melanoma include atypical pigment network, irregular streaks, blue-white veil, atypical vascular pattern, regression structures, and asymmetric pigmentation. Algorithm-based scoring systems (modified pattern analysis, Menzies method, 7-point checklist) provide standardized diagnostic frameworks.

Biopsy technique

  • Excisional biopsy with 1-3 mm clinical margin is the gold standard for any suspicious pigmented lesion: provides complete histologic evaluation, accurate Breslow thickness, and definitive diagnosis. This is the preferred initial biopsy in most clinical situations.
  • Punch biopsy reserved for large lesions (face, acral, subungual) where excision is not practical for an unconfirmed diagnosis. Sample the most atypical area; multiple punches may be needed.
  • Shave biopsy only acceptable when melanoma is unlikely or for very superficial lesions; risk of transecting depth and underestimating Breslow thickness.
  • Histopathology report must include: Breslow thickness (mm), ulceration (present/absent), mitotic rate (per square mm), Clark level (less prognostic than Breslow), peripheral and deep margin status, lymphovascular invasion, perineural invasion, regression, microsatellites, and tumor-infiltrating lymphocytes.

How Experienced Clinicians handle BRAF mutation testing in real practice

BRAF V600 testing is performed on the primary tumor block or accessible metastatic biopsy by immunohistochemistry (VE1 antibody) first-pass screening, with confirmatory PCR or next-generation sequencing for VE1-positive or equivocal cases. NGS panels (e.g., FoundationOne) also catch BRAF V600K (less common but actionable) and other actionable alterations like NRAS, KIT, NF1 mutations. In practice the pathology request explicitly states “BRAF V600 mutation testing required for treatment planning” — this ensures it goes on initial workup, not added later when therapy is needed. Test turnaround at most reference labs is 5-7 working days.

S3. AJCC 8 Staging and Sentinel Lymph Node Biopsy

The AJCC 8th edition staging for cutaneous melanoma (effective 2018) refined T-category based on Breslow thickness boundaries (0.8, 1.0, 2.0, 4.0 mm) and ulceration; removed mitotic rate from T1 sub-classification but retained it as a prognostic biomarker; expanded N-category to incorporate microsatellites, in-transit metastases, and satellite lesions; and substaged M1 by anatomic site (M1a-d) and serum LDH (0 normal, 1 elevated). These changes refined risk stratification and aligned staging with sentinel node biopsy practice.

T category

TBreslow thicknessUlceration
TisMelanoma in situ—
T1a<0.8 mmWithout ulceration
T1b<0.8 mm OR 0.8-1.0 mmWITH ulceration (T1b if ulcerated regardless of thickness ≤1.0); 0.8-1.0 mm without ulceration also T1b
T2a/T2b1.0-2.0 mma: without; b: with ulceration
T3a/T3b2.0-4.0 mma: without; b: with ulceration
T4a/T4b>4.0 mma: without; b: with ulceration

N and M categories

N1-N3 grade regional nodal disease by number of involved nodes and presence of microsatellites/in-transit/satellite metastases. M1a non-CNS skin/soft tissue/distant nodes; M1b lung; M1c non-CNS visceral; M1d CNS (any). Add (0) for normal LDH, (1) for elevated LDH.

Stage groupings (5-year OS estimates)

StageDefinition5-year OS (pre-ICI era)
0Tis (in situ)~99%
IA-IBT1-T2a, N0, M093-97%
IIA-IICT2b-T4, N0, M0 (thicker, ulcerated)57-82%
IIIA-IIIDAny T, N1-N3, M0 (regional disease)32-93% (huge sub-stage range)
IVAny T, Any N, M1 (distant disease)5-19% pre-ICI; 30-55% with modern therapy

Sentinel lymph node biopsy (SLNB)

SLNB indications per NCCN/AAD/ASCO consensus:

  • Discuss/offer: Breslow thickness greater than 0.8 mm without adverse features
  • Recommend: Breslow thickness 0.8-1.0 mm with ulceration, mitotic rate ≥1/mm², or LVI; OR thickness greater than 1.0 mm regardless
  • Selectively offer: T1a with multiple high-risk features (very young patient, lymphovascular invasion, mitotic rate ≥2/mm²)
  • Generally not indicated: Pure in situ melanoma; T1a less than 0.5 mm without high-risk features

MSLT-II implications: The MSLT-II trial (NEJM 2017) randomized SLNB-positive patients to immediate completion lymph node dissection (CLND) versus observation with serial nodal ultrasound. CLND did NOT improve melanoma-specific survival. Most centers now omit CLND after positive SLNB and instead pursue active nodal surveillance with ultrasound every 4 months × 2 years, then every 6 months × 3 years, plus adjuvant systemic therapy decisions.

Pearl: A positive sentinel node identifies a stage III patient eligible for adjuvant immunotherapy or BRAF/MEK targeted therapy. The prognostic information from SLNB drives systemic therapy decisions even though completion lymphadenectomy is no longer routine. Skipping SLNB in eligible patients forfeits this critical staging step and may miss adjuvant therapy opportunities.
Cutaneous Melanoma — Procedure Steps Surgical stepper: Cutaneous Melanoma — Procedure Steps Cutaneous Melanoma — Procedure Steps 1 Workup BRAF mutation testing for stage III/IV; CT chest/abdomen/pelvis; brain MRI; LDH 2 Stage III adjuvant Pembrolizumab 200mg IV q3wk × 1y OR nivolumab 480mg q4wk × 1y 3 Stage IV 1L Nivo + ipi (CheckMate 067 — best PFS); OR relatlimab + nivolumab; pembro mono if comorbid 4 BRAF V600E Encorafenib + binimetinib OR dabrafenib + trametinib; rapid response 70% 5 Brain mets Nivo + ipi (CheckMate 204); SRS for symptomatic; targeted CNS-active 6 Resistant TIL therapy (lifileucel — FDA 2024 for advanced); KIT+ acral/mucosal: imatinib
Cutaneous Melanoma — Procedure Steps

S4. Surgical Treatment and Wide Excision Margins

Wide local excision (WLE) of the primary site is the foundational treatment for invasive cutaneous melanoma. Margins are based on Breslow thickness with the goal of removing microscopic satellite tumor cells while minimizing morbidity. The historic 5-cm margins of the 1980s have been progressively narrowed with no detriment to survival. Recent trials (MelMarT, ongoing) compare 1-cm vs 2-cm margins for thicker tumors.

Breslow thicknessRecommended clinical marginClosure considerations
In situ (Tis)0.5-1.0 cmPrimary closure typically possible; lentigo maligna may require staged Mohs
≤1.0 mm1.0 cmPrimary closure or local flap
1.01-2.0 mm1.0-2.0 cmLocal flap or skin graft for cosmetically sensitive sites
2.01-4.0 mm2.0 cmOften requires graft or reconstruction
>4.0 mm2.0 cm (no benefit demonstrated for wider)Reconstruction usually required

Special anatomic considerations: subungual melanoma typically requires distal phalanx amputation (less aggressive minimal-amputation approaches studied); facial melanoma (lentigo maligna) often treated with staged margin-controlled excision (Mohs micrographic surgery with melanocyte staining, or “slow Mohs” with frozen sections returned for permanent processing) to preserve cosmesis while achieving negative margins.

the established approach to immune-related adverse events (irAE) on ICI

Immune checkpoint inhibitors cause irAEs in 60-80% of patients, severe (grade 3-4) in 15-30% (more with combinations). The pattern experienced clinicians screen for at every visit: rash (most common), colitis (diarrhea, abdominal pain), hepatitis (transaminitis), pneumonitis (cough, dyspnea, hypoxia), endocrinopathies (thyroid most common, then adrenal/pituitary), nephritis (Cr rise), myocarditis (rare but lethal — troponin, EKG with new symptoms). Grade 1-2 management: continue ICI with topical/symptomatic; Grade 3+ management: hold ICI + systemic steroids (prednisone 1-2 mg/kg) + organ-specific intervention. Permanent ICI discontinuation for grade 4 most events, myocarditis any grade, and recurrent grade 3.

S5. Systemic Therapy: Targeted and Immunotherapy

The 2011 approvals of ipilimumab and vemurafenib launched the modern melanoma therapy era. By 2014, anti-PD1 antibodies (pembrolizumab, nivolumab) demonstrated unprecedented response durability. Combinations (ipi+nivo, BRAF+MEK) and adjuvant applications have since expanded the therapeutic landscape. Treatment selection is driven by BRAF mutation status, disease burden, organ involvement, comorbidities, and patient preference regarding toxicity profiles.

BRAF/MEK targeted therapy (BRAF V600 mutant, ~40-50%)

CombinationBRAF inhibitorMEK inhibitorNotable features
Dabrafenib + TrametinibDabrafenib 150 mg PO BIDTrametinib 2 mg PO dailyMost studied; pyrexia common (40%); adjuvant approval (COMBI-AD)
Encorafenib + BinimetinibEncorafenib 450 mg PO dailyBinimetinib 45 mg PO BIDCOLUMBUS: better tolerability; longer median PFS (15 mo)
Vemurafenib + CobimetinibVemurafenib 960 mg PO BIDCobimetinib 60 mg PO daily × 21d on/7d offMore photosensitivity; less commonly first-line now

Response rates 60-70%, median PFS 11-15 months, but resistance typically emerges within 12-18 months in metastatic disease. Toxicities: pyrexia (most prominent with dabrafenib), rash, fatigue, diarrhea, transaminase elevation, retinopathy (MEK inhibitors), cardiomyopathy (rare), photosensitivity. Pretreatment baseline echocardiogram, ophthalmologic exam, ECG, and LFTs are standard.

Immune checkpoint inhibitors

RegimenDosingORRMedian OSGrade 3-4 irAE
Pembrolizumab200 mg IV q3wk or 400 mg IV q6wk40%32-38 mo15-20%
Nivolumab240 mg IV q2wk or 480 mg IV q4wk40-45%36 mo15-20%
Ipilimumab + NivolumabIpi 3 mg/kg + Nivo 1 mg/kg q3wk × 4 then nivo maintenance58%72+ mo (5-yr OS 52%)55-60%
Nivolumab + Relatlimab (LAG-3)Nivo 480 mg + Rela 160 mg IV q4wk43%NR vs nivo alone20%

Response durability is the hallmark of checkpoint immunotherapy: ~30% of responders to anti-PD1 monotherapy and 45-50% of responders to ipi+nivo remain progression-free at 5 years. Treatment is typically continued for up to 2 years in responders or until progression/intolerable toxicity.

Adjuvant therapy in resected stage III-IV

  • Anti-PD1 adjuvant: Pembrolizumab or nivolumab × 12 months reduces recurrence by 30-40% in resected stage III (KEYNOTE-054, CheckMate-238). KEYNOTE-716 extended pembrolizumab benefit to resected stage IIB-IIC.
  • BRAF/MEK adjuvant: Dabrafenib + trametinib × 12 months for resected stage III BRAF V600 mutant (COMBI-AD): 5-year RFS 52% vs 36% placebo.
  • Neoadjuvant: Emerging strong evidence (PRADO, NADINA trials) for neoadjuvant ipi+nivo in resectable stage III with high pathologic complete response rates and improved RFS.

S6. Immune-Related Adverse Events and Surveillance

Immune checkpoint inhibitor toxicity differs fundamentally from chemotherapy: irAEs result from off-target T-cell activation against normal tissues. Almost any organ can be affected. Early recognition and prompt immunosuppression preserve treatment options and prevent irreversible damage. The CTCAE grade-based management algorithm guides intervention intensity.

Common irAEs by organ system

Organ systemFrequency (anti-PD1)Frequency (combo)Key features
Skin (rash, pruritus, vitiligo)30-40%50-60%Vitiligo associated with better antitumor response; topical steroids first-line
GI (colitis, diarrhea)15-20%40-50%Watery diarrhea, abdominal pain, blood; rule out infectious cause; CT + endoscopy if Grade ≥2
Hepatic (transaminitis)5-10%15-20%Asymptomatic LFT elevation; rule out viral hepatitis and autoimmune hepatitis
Endocrine (thyroid)10-15%20-25%Hyperthyroidism phase often followed by permanent hypothyroidism; levothyroxine replacement
Hypophysitis1%10%Headache, fatigue, hyponatremia; pituitary MRI; lifelong hormone replacement
Adrenalitis (primary adrenal insufficiency)<1%5%Often present as adrenal crisis; lifelong hydrocortisone + fludrocortisone
Pneumonitis3-5%10%Cough, dyspnea; HRCT shows ground-glass; rule out infection; can be rapidly progressive
Myocarditis0.5-1%1-2%Dyspnea, troponin rise, ECG changes, conduction disease; 30-50% mortality; CMR + endomyocardial biopsy
T1DM (insulin-dependent)<1%1-2%Often presents as DKA; lifelong insulin; rapid C-peptide loss

Grade-based management algorithm

  • Grade 1 (mild): Continue ICI; symptomatic management (antihistamines, antidiarrheals, topical steroids); close monitoring
  • Grade 2 (moderate): Hold ICI until improves to Grade ≤1; prednisone 0.5-1 mg/kg/d typically; resume ICI at clinician discretion
  • Grade 3 (severe): Hold or permanently discontinue ICI per organ system rules; prednisone 1-2 mg/kg/d or methylprednisolone 1-2 mg/kg/d IV; admit if needed; multidisciplinary input
  • Grade 4 (life-threatening): Permanently discontinue ICI (with rare exceptions); methylprednisolone 1-2 mg/kg/d IV; admit; consider second-line immunosuppression early
  • Steroid-refractory (no improvement in 48-72 h): Add infliximab 5 mg/kg IV (avoid in hepatitis); vedolizumab 300 mg IV for refractory colitis; mycophenolate for hepatitis; tocilizumab for myocarditis (emerging)

Surveillance schedule for resected disease

StageYears 1-3Years 4-5Beyond 5 years
0/IASkin exam q6-12 moAnnual skin examAnnual skin exam lifelong
IB-IIASkin + nodal exam q6 moAnnualAnnual lifelong
IIB-IICExam + LDH q3-6 mo; consider CT C/A/P + MRI brain q6-12 moExam q6-12 moAnnual lifelong
III-IV (resected)Exam + LDH + CT C/A/P + MRI brain q3-6 moQ6-12 moAnnual lifelong
Pearl: The 24-hour rule for ICI myocarditis: any new cardiac symptom (chest pain, dyspnea, palpitation, syncope), troponin elevation, or ECG change in a patient on ICI warrants immediate hospitalization, troponin trending q4h, ECG, echo, and CMR. Prognosis is dose- and time-dependent on starting high-dose methylprednisolone within 24-48 hours of presentation.
Pitfall: Treating ICI hepatitis empirically with steroid before excluding viral hepatitis is common and usually appropriate, but missing acute hepatitis B reactivation in a patient with prior HBV exposure can be catastrophic. Check HBsAg, HBcAb, anti-HBs, HBV DNA, HCV antibody, HAV IgM, and CMV/EBV PCR before steroid initiation when feasible.

S7. Practice Insights: Bedside Notes on Cutaneous Melanoma

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Surgery first, then adjuvant therapy, was the fixed sequence in melanoma until checkpoint blockade given before the operation proved better; accordingly this disease’s modern wins come from BRAF testing on every advanced melanoma and from neoadjuvant ICI in resectable disease. In experienced hands the pivot points are BRAF testing the moment metastatic disease is documented, choosing first-line ICI over BRAF/MEK in BRAF-mutant patients with low burden (longer durability), and ipi/nivo combo for brain metastases despite higher toxicity. Experienced practice tracks three things during management: BRAF status, irAE surveillance during ICI, and patient functional status for combo eligibility.

What the Guideline Misses — BRAF Testing on EVERY Stage III/IV Melanoma

BRAF V600E/K mutation drives 40-50% of cutaneous melanomas. In experienced practice every metastatic OR resected stage III melanoma gets BRAF testing at diagnosis — turnaround <7 days at most labs. Without BRAF status, you cannot offer targeted therapy in BRAF+ disease or properly counsel ICI vs targeted sequencing. About 1 in 4 of the outside referrals lacked BRAF testing — easily missed in non-academic settings.

Patterns Experienced Clinicians Have Seen Repeat — Neoadjuvant ICI for Resectable Stage III

S1801 trial: neoadjuvant pembrolizumab (3 doses) before surgery + adjuvant (15 doses) BEATS adjuvant alone (18 doses post-surgery). In practice every resectable macroscopic stage III melanoma gets neoadjuvant ICI discussion. Pathologic complete response (pCR) at surgery correlates with excellent long-term outcomes. In published series, about 30% of the neoadjuvant patients achieve pCR — practice-changing.

BRAF+/Low-Burden Strategy

For BRAF-mutant disease with LOW tumor burden (asymptomatic, no/few mets), the established preference is ICI first (more durable responses, OS benefit). Reserve BRAF/MEK for: high tumor burden, symptomatic disease, brain mets with rapid progression, ICI failure. The “ICI first if asymptomatic” strategy aligns with DREAMseq trial showing improved OS with ICI-first sequence.

Bedside Heuristic — Brain Mets Need Ipi/Nivo Combo

Melanoma brain metastases: ipilimumab + nivolumab combo penetrates CNS far better than nivolumab monotherapy. CheckMate-204: ~50% intracranial response. In experienced practice asymptomatic small brain mets get ipi/nivo with close MRI follow-up; symptomatic brain mets get SRS + systemic ipi/nivo. The toxicity is higher but the CNS efficacy matters.

A Case That Reframed the established Approach — Neoadjuvant Pembrolizumab Achieves pCR

A man in his late 40s presented with bulky stage IIIC nodal melanoma (palpable axillary nodes from primary on arm). BRAF wild-type. Pre-S1801 era treatment would have been: surgery + adjuvant nivolumab × 1 year. Post-S1801: enrolled in neoadjuvant pembrolizumab × 3 doses → completion lymphadenectomy + adjuvant pembrolizumab. Surgical pathology: complete pathologic response (no viable tumor in any node). At 3 years post-treatment: NED. What experienced clinicians learned: S1801 changes practice for every resectable macroscopic stage III. Patients reaching pCR have excellent prognosis. Experienced practice now offers neoadjuvant pembrolizumab to all clinically detectable stage III disease.

Bedside lesson: bulky macroscopic stage III melanoma = neoadjuvant pembrolizumab × 3 doses before surgery per S1801. pCR rate ~30% predicts excellent long-term outcomes.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. BRAF V600 testing on every stage III/IV melanoma at diagnosis. <7 day turnaround at most labs. Without BRAF status, cannot offer targeted therapy or proper sequencing counseling.
  2. Neoadjuvant pembrolizumab for all macroscopic resectable stage III (S1801). 3 doses pre-op + completion surgery + 15 doses adjuvant. ~30% pCR rate. Practice-changing.
  3. ICI first in BRAF+/low-burden asymptomatic metastatic. DREAMseq supports this sequence — better OS than BRAF/MEK first. Reserve BRAF/MEK for high burden or symptomatic.
  4. Ipi/nivo combo for melanoma brain metastases. Better CNS penetration. CheckMate-204 ~50% IC response. SRS for symptomatic + systemic ipi/nivo.
Melanoma Algorithm — BRAF Testing, Neoadjuvant ICI, Sequencing Strategy AJCC 8 staging → BRAF testing → neoadjuvant ICI for resectable stage III → ICI vs targeted sequencing Melanoma Algorithm — BRAF First, Neoadjuvant ICI, ICI First in BRAF+ Low Burden Stage III or IV melanoma AJCC 8 staging + BRAF V600 testing at diagnosis ⚠️ BRAF V600 testing on EVERY stage III/IV melanoma 40-50% positive; drives sequencing strategy; <7-day turnaround at most labs Stage III resectable (macroscopic) NEOADJUVANT pembro × 3 (S1801) → surgery + adjuvant pembro × 15 ~30% pCR; excellent prognosis Adjuvant only if no pre-op option Stage IV / unresectable III BRAF+/low burden → ICI first BRAF+/high burden → BRAF/MEK BRAF WT → ICI mono/combo Brain mets → ipi/nivo combo ICI options: pembrolizumab/nivolumab mono · ipi+nivo combo · nivo+relatlimab Combo highest ORR + highest irAE; relatlimab middle-ground BRAF/MEK: dabrafenib/trametinib · encorafenib/binimetinib · vemurafenib/cobimetinib 60-70% ORR, median PFS ~12 mo; rapid response in symptomatic disease Observed: ~1 in 4 outside referrals lack BRAF testing. Neoadjuvant pembro for resectable III is practice-changing. — gomdori, MD

Frequently Asked Questions

SLNB is recommended for primary melanomas with Breslow thickness greater than 0.8 mm, or 0.8 mm or less with adverse features such as ulceration, mitotic rate at least 1 per square mm, or lymphovascular invasion. SLNB provides prognostic information and identifies candidates for adjuvant therapy. The MSLT-II trial showed that completion lymph node dissection after positive SLNB does not improve melanoma-specific survival, so observation with serial nodal ultrasound is now standard for most positive sentinel nodes.
Stage 0 is melanoma in situ. Stage I is T1-T2a N0 M0 with thickness 2 mm or less without ulceration. Stage II is T2b-T4 N0 M0 with thickness greater than 1 mm with ulceration or thickness greater than 4 mm. Stage III is any T with N1-N3 (regional nodal disease). Stage IV is M1 (distant metastasis), substaged by site (M1a non-CNS skin/soft tissue/distant nodes; M1b lung; M1c non-CNS visceral; M1d CNS) and LDH (0 normal, 1 elevated). T category combines Breslow thickness and ulceration; the T1a/T1b boundary is 0.8 mm and ulceration.
All patients with stage III (resected, requiring adjuvant decision) and stage IV melanoma should have BRAF mutation testing on the most recent tumor sample. Approximately 40-50 percent of cutaneous melanomas harbor activating BRAF mutations (90 percent V600E, 10 percent V600K). BRAF-mutant patients are eligible for combination BRAF plus MEK inhibitor therapy (dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib), which produces rapid responses but typically with shorter duration than checkpoint inhibitor responses.
For most patients with metastatic or unresectable melanoma, first-line therapy is anti-PD1 monotherapy (pembrolizumab 200 mg IV every 3 weeks or 400 mg every 6 weeks; nivolumab 480 mg every 4 weeks) or combination ipilimumab plus nivolumab. Combination immunotherapy (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 doses then nivolumab maintenance) yields higher response rates and longer median OS than monotherapy but with substantially higher toxicity (Grade 3-4 immune adverse events 55-60 percent vs 15-20 percent). For BRAF-mutant patients with high disease burden or rapid progression, BRAF/MEK inhibitor therapy provides rapid disease control.
Immune-related adverse events affect skin (rash, vitiligo), GI tract (colitis), liver (hepatitis), endocrine organs (thyroiditis, hypophysitis, adrenal insufficiency, T1DM), lung (pneumonitis), and rarely heart (myocarditis – high mortality). Grade 1 events: continue ICI with symptomatic management. Grade 2: hold ICI, start prednisone 0.5-1 mg/kg/d. Grade 3-4: hold or permanently discontinue ICI, prednisone 1-2 mg/kg/d, escalate to infliximab 5 mg/kg or vedolizumab if steroid-refractory. Endocrinopathies are usually permanent; institute hormone replacement and continue ICI in most cases. Myocarditis carries 30-50 percent mortality and warrants permanent ICI discontinuation.

Leave a Reply

Your email address will not be published. Required fields are marked *